A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Pancreatic Ductal Adenocarcinoma · Colorectal Cancer · KRAS G12D · KRAS G12R · KRAS G12V · KRAS G12A · KRAS G12C · KRAS G12S · KRAS G13D · NRAS G12D · NRAS G12R · NRAS G12V · NRAS G12C · NRAS G12S
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 158 (final count)
- Started
- Apr 14, 2023
- Main results expected
- Apr 20, 2026
- Fully finished
- Nov 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Evaluate the safety of ELI-002 7P
Measured over: 28 days after the first dose of ELI-002 7P
Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival)
Measured over: After the last radiographic assessment at Visit 26 (Week 150)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05726864 · record last updated 2026-07-10 · checked 2026-11-09 15:47 UTC